Glucose Aguettant

Glucose Aguettant is an intravenous solution that contains glucose monohydrate as its sole active ingredient. It is supplied in a sterile liquid form intended for infusion, and is marketed within the European Union. The product provides a readily available source of glucose for patients who require rapid energy supplementation through the bloodstream. No additional excipients or strength specifications are listed as required by clinical protocols.

Glucose Aguettant is used when a rapid increase in blood glucose is needed, typically in clinical settings that involve intravenous therapy.

- Treatment of hypoglycemia when oral glucose is not feasible. - Energy source during surgery or anesthesia to maintain metabolic balance. - Support for patients receiving parenteral nutrition who require carbohydrate supplementation. - Management of electrolyte imbalances where glucose infusion helps intracellular fluid shifts. - Use in diagnostic procedures such as glucose tolerance testing when administered intravenously. - Adjunctive therapy for certain metabolic disorders under medical supervision.

Glucose Aguettant may be associated with a range of adverse reactions, most of which are related to the infusion of a carbohydrate solution.

Common: - Mild hyperglycemia or transient rise in blood glucose levels. - Local irritation or pain at the infusion site. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness during rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reaction such as rash, itching, or anaphylaxis. - Electrolyte disturbances, particularly hyponatremia. - Fluid overload causing pulmonary edema.

When administering Glucose Aguettant, healthcare professionals should observe several precautionary measures to ensure patient safety and appropriate therapeutic effect.

- Verify patient’s blood glucose level before infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use aseptic technique to maintain sterility of the intravenous solution. - Monitor electrolytes, especially sodium and potassium, during prolonged administration. - Consider contraindications in patients with known hypersensitivity to glucose solutions. - Assess for signs of infection at the catheter site throughout therapy.

Glucose Aguettant can interact with other medications or clinical conditions, and awareness of these interactions helps prevent complications.

Avoid: - Concurrent use of insulin or other hypoglycemic agents without dose adjustment, which may cause severe hypoglycemia. - Co-administration with high‑dose diuretics that may exacerbate electrolyte imbalances.

Use with caution: - Concurrent intravenous fluids containing dextrose or other carbohydrates, to avoid cumulative glucose load. - Patients receiving beta‑blockers, as they may mask symptoms of hypoglycemia. - Use in combination with corticosteroids, which can increase blood glucose levels.